Armen said CFIUS ultimately worked through the process and the deal closed, enabling Agenus to move forward with 2026 plans. Armen said Zydus retained the Emeryville team, calling it a “superstar team,” and noted that Agenus Chief Manufacturing Officer Al Dodson would become a Zydus executive serving both companies. Armen added that the collaboration expanded beyond manufacturing after Agenus presented data to key opinion leaders in India. Armen framed the AAC expansion as evidence of urgency and a willingness to allow access while confirmatory trials continue. Iglesias described access routes centered on France’s reimbursed compassionate access framework, as well as participation by non-French patients through cross-country healthcare arrangements, insurance reimbursement in their home countries, or self-pay options.